We are a pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers. Our focus is on activating SHIP1, believed to decrease the inflammatory process, thereby reducing inflammation and inflammatory pain.

Preclinical and clinical studies have shown inflammation can be reduced by administration of compounds that activate SHIP1. If the PI3K pathway is overactive, immune cells may produce an abundance of pro-inflammatory signaling molecules, migrating to and concentrating in tissues, resulting in excessive or chronic inflammation.5 Compounds activating SHIP1 may reduce the function and migration of immune cells producing an anti-inflammatory effect. In addition, because SHIP1 is predominantly present in immune cells, off-tissue toxicities may be minimized.

Our longer-term strategy is to leverage our SHIP1 technology to develop drug candidates for the treatment of inflammatory diseases and cancer.



1 Hanno P, Cervigni M, Dinis P, et al. Bladder Pain Syndrome. In: Abrams P, Cardozo L, Wagg A, Wein A, eds. Incontinence. 6th ed. 2017:2206-2275.

2 Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186:540-544.

3 Suskind AM, Berry SH, Ewing BA, et al. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men; results of the RAND interstitial cystitis epidemiology (RICE) male study. J Urol. 2013;189:141-145.

4 Daniels N, et al. J Natl Med Assoc. 2007; 99(5): 509-516.

5 Patel, RK & Mohan, C. Immunol Res (2005) 31: 47.